chemotherapy/diarrhea

FIELD OF THE INVENTION The present invention relates to glucagon-like-peptide-2 (GLP-2) analogues and their medical use, for example in the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates generally to a method for treating acute and severe diarrhea as may occur during chemotherapy or acute narcotic withdrawal. More particularly, the present invention provides such a method utilizing the somatostatin analogue octreotide. BACKGROUND

BACKGROUND 1. Field of the Invention The teachings provided herein relate to methods of treating a gastrointestinal spasms associated with chemotherapy or radiation therapy. 2. Description of Related Art Antispasmodics can be used to prevent spasms of the stomach, intestine, uterus, or urinary

FIELD OF THE INVENTION The present invention relates generally to a method for treating acute and severe diarrhea as may occur during chemotherapy or acute narcotic withdrawal. More particularly, the present invention provides such a method utilizing the somatostatin analogue octreotide. BACKGROUND

BACKGROUND OF THE INVENTION The present invention is directed to compounds and compositions containing said compounds which bind selectively to somatostatin receptor subtypes and the use of said compounds for treating medical disorders which are mediated by somatostatin receptor subtypes.

BACKGROUND Camptothecin (CPT)-derived drugs, such as irinotecan (CPT-11), are typically used for treating solid brain, colon, and lung tumors, as well as for treating refractory forms of leukemia and lymphoma. See Pommier Nat. Rev. Cancer, 6(10):789 802. The antineoplastic efficacy of CPT-11 is

FIELD OF INVENTION The present invention is directed to modulators of the TGR5 receptor useful in the treatment of TGR5 mediated diseases or disorders. Specifically, the invention is concerned with compounds and compositions thereof, which activate the TGR5 receptor, methods of treating diseases or

BACKGROUND OF THE INVENTION Gastrointestinal stimulation, or pacing, was advocated as a possible treatment for gastric motor dysfunction as early as 1963. Experimentation in the late 1960s and early 1970s, began to demonstrate the significance of gastrointestinal myoelectrical activity and its

2. FIELD OF THE INVENTION The invention encompasses novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such

2. FIELD OF THE INVENTION The invention encompasses novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such

2. FIELD OF THE INVENTION The invention encompasses novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such

2. FIELD OF THE INVENTION The invention encompasses novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such

2. FIELD OF THE INVENTION The invention encompasses novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such

BACKGROUND OF THE INVENTION This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the

BACKGROUND OF THE INVENTION This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives